Neuronal accumulation of glucosylceramide in a mouse model of neuronopathic Gaucher disease leads to neurodegeneration

被引:115
作者
Farfel-Becker, Tamar [1 ]
Vitner, Einat B. [1 ]
Kelly, Samuel L. [3 ,4 ]
Bame, Jessica R. [3 ,4 ]
Duan, Jingjing [3 ,4 ]
Shinder, Vera [2 ]
Merrill, Alfred H., Jr. [3 ,4 ]
Dobrenis, Kostantin [5 ]
Futerman, Anthony H. [1 ]
机构
[1] Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel
[2] Weizmann Inst Sci, Dept Chem Res Support, IL-76100 Rehovot, Israel
[3] Georgia Inst Technol, Sch Biol, Atlanta, GA 30332 USA
[4] Georgia Inst Technol, Petit Inst Bioengn & Biosci, Atlanta, GA 30332 USA
[5] Yeshiva Univ Albert Einstein Coll Med, Dominick P Purpura Dept Neurosci, Bronx, NY 10461 USA
关键词
PARKINSONS-DISEASE; GLUCOSYLSPHINGOSINE ACCUMULATION; GLUCOCEREBROSIDASE MUTATIONS; STORAGE DISORDERS; FINE STRUCTURE; INFANTILE; TYPE-2; NEUROPATHOLOGY; SPHINGOLIPIDS; METABOLISM;
D O I
10.1093/hmg/ddt468
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Gaucher disease has recently received wide attention due to the unexpected discovery that it is a genetic risk factor for Parkinsons disease. Gaucher disease is caused by the defective activity of the lysosomal enzyme, glucocerebrosidase (GCase; GBA1), resulting in intracellular accumulation of the glycosphingolipids, glucosylceramide and psychosine. The rare neuronopathic forms of GD (nGD) are characterized by profound neurological impairment and neuronal cell death. We have previously described the progression of neuropathological changes in a mouse model of nGD. We now examine the relationship between glycosphingolipid accumulation and initiation of pathology at two pre-symptomatic stages of the disease in four different brain areas which display differential degrees of susceptibility to GCase deficiency. Liquid chromatography electrospray ionization tandem mass spectrometry demonstrated glucosylceramide and psychosine accumulation in nGD brains prior to the appearance of neuroinflammation, although only glucosylceramide accumulation correlated with neuroinflammation and neuron loss. Levels of other sphingolipids, including the pro-apoptotic lipid, ceramide, were mostly unaltered. Transmission electron microscopy revealed that glucosylceramide accumulation occurs in neurons, mostly in the form of membrane-delimited pseudo-tubules located near the nucleus. Highly disrupted glucosylceramide-storing cells, which are likely degenerating neurons containing massive inclusions, numerous autophagosomes and unique ultrastructural features, were also observed. Together, our results indicate that a certain level of neuronal glucosylceramide storage is required to trigger neuropathological changes in affected brain areas, while other brain areas containing similar glucosylceramide levels are unaltered, presumably because of intrinsic differences in neuronal properties, or in the neuronal environment, between various brain regions.
引用
收藏
页码:843 / 854
页数:12
相关论文
共 53 条
  • [1] ADACHI M, 1967, ARCH PATHOL, V83, P513
  • [2] The efficacy of enzyme replacement therapy in patients with chronic neuronopathic Gaucher's disease
    Altarescu, G
    Hill, S
    Wiggs, E
    Jeffries, N
    Kreps, C
    Parker , CC
    Brady, RO
    Barton, NW
    Schiffmann, R
    Bannarjee, TK
    Crutchfield, K
    Frei, K
    McKee, MA
    Moore, DF
    Tournay, A
    [J]. JOURNAL OF PEDIATRICS, 2001, 138 (04) : 539 - 547
  • [3] [Anonymous], 2001, METABOLIC MOL BASES
  • [4] The Role of the Ceramide Acyl Chain Length in Neurodegeneration: Involvement of Ceramide Synthases
    Ben-David, Oshrit
    Futerman, Anthony H.
    [J]. NEUROMOLECULAR MEDICINE, 2010, 12 (04) : 341 - 350
  • [5] BENNETT SAL, 1995, ACTA NEUROPATHOL, V89, P126
  • [6] BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911
  • [7] Bogoeva Biljana, 2001, Acta Medica Croatica, V55, P131
  • [8] Emerging pathways in genetic Parkinson's disease: Potential role of ceramide metabolism in Lewy body disease
    Bras, Jose
    Singleton, Andrew
    Cookson, Mark R.
    Hardy, John
    [J]. FEBS JOURNAL, 2008, 275 (23) : 5767 - 5773
  • [9] Systemic Delivery of a Glucosylceramide Synthase Inhibitor Reduces CNS Substrates and Increases Lifespan in a Mouse Model of Type 2 Gaucher Disease
    Cabrera-Salazar, Mario A.
    DeRiso, Matthew
    Bercury, Scott D.
    Li, Lingyun
    Lydon, John T.
    Weber, William
    Pande, Nilesh
    Cromwell, Mandy A.
    Copeland, Diane
    Leonard, John
    Cheng, Seng H.
    Scheule, Ronald K.
    [J]. PLOS ONE, 2012, 7 (08):
  • [10] CERVOSNAVARRO J, 1990, CLIN NEUROPATHOL, V9, P310